Keith Fay

1.7k total citations
30 papers, 354 citations indexed

About

Keith Fay is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Keith Fay has authored 30 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 13 papers in Oncology and 10 papers in Genetics. Recurrent topics in Keith Fay's work include Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Acute Myeloid Leukemia Research (6 papers). Keith Fay is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Acute Myeloid Leukemia Research (6 papers). Keith Fay collaborates with scholars based in Australia, United States and France. Keith Fay's co-authors include Matthew Greenwood, Ian Kerridge, Chris Arthur, Luke Coyle, William Stevenson, Julian Lindsay, David Valcárcel, Liliane Kappeler, Carlo Casali and Isabel Illa and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Keith Fay

28 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keith Fay Australia	10	105	97	94	86	70	30	354
László Rejtő Hungary	9	62 0.6×	60 0.6×	108 1.1×	39 0.5×	44 0.6×	33	376
Tomoo Osumi Japan	11	104 1.0×	83 0.9×	110 1.2×	54 0.6×	35 0.5×	54	374
R. Flener Austria	13	88 0.8×	35 0.4×	107 1.1×	49 0.6×	134 1.9×	30	435
Alisa B. Lee‐Sherick United States	13	94 0.9×	46 0.5×	146 1.6×	85 1.0×	32 0.5×	24	651
Masaaki� Hotta Japan	11	66 0.6×	41 0.4×	48 0.5×	57 0.7×	50 0.7×	40	277
Benjamin B. Mull United States	11	132 1.3×	17 0.2×	174 1.9×	34 0.4×	9 0.1×	12	410
Emilie Bittoun Belgium	8	312 3.0×	259 2.7×	97 1.0×	39 0.5×	51 0.7×	9	489
Tatianna Larman United States	8	269 2.6×	25 0.3×	257 2.7×	113 1.3×	50 0.7×	24	606
Limin Xing China	13	104 1.0×	19 0.2×	140 1.5×	65 0.8×	89 1.3×	103	631
Jean Marie Leclerc Canada	11	128 1.2×	12 0.1×	202 2.1×	52 0.6×	24 0.3×	15	488

Countries citing papers authored by Keith Fay

Since Specialization

Citations

This map shows the geographic impact of Keith Fay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Fay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Fay more than expected).

Fields of papers citing papers by Keith Fay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Fay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Fay. The network helps show where Keith Fay may publish in the future.

Co-authorship network of co-authors of Keith Fay

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Fay. A scholar is included among the top collaborators of Keith Fay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Fay. Keith Fay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bartlett, Nancy L., Laurie H. Sehn, Sarit Assouline, et al.. (2024). Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II. Blood. 144(Supplement 1). 1645–1645. 4 indexed citations

Schuster, Stephen J., Laurie H. Sehn, Nancy L. Bartlett, et al.. (2024). IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study. Clinical Lymphoma Myeloma & Leukemia. 24. S497–S497.

Withers, Barbara, Andrew Jabbour, Sam Milliken, et al.. (2022). Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis. Internal Medicine Journal. 52(10). 1826–1830. 4 indexed citations

Lindsay, Julian, Jad Othman, Sebastiaan J. van Hal, et al.. (2021). SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation. Open Forum Infectious Diseases. 8(11). ofab502–ofab502. 11 indexed citations

Lindsay, Julian, Jad Othman, Michelle K. Yong, et al.. (2021). Dynamics of Epstein–Barr virus on post‐transplant lymphoproliferative disorders after antithymocyte globulin‐conditioned allogeneic hematopoietic cell transplant. Transplant Infectious Disease. 23(5). e13719–e13719. 7 indexed citations

Shen, Yandong, Luke Coyle, Ian Kerridge, et al.. (2021). Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. SHILAP Revista de lepidopterología. 3(1). 129–138. 14 indexed citations

Lindsay, Julian, Jad Othman, Ian Kerridge, et al.. (2020). Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre‐transplant predictors of survival, reactivation, and spontaneous clearance. Transplant Infectious Disease. 23(3). e13548–e13548. 8 indexed citations

Othman, Jad, Christopher Arthur, Keith Fay, et al.. (2020). Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma. Bone Marrow Transplantation. 55(7). 1460–1463. 3 indexed citations

Coleman, Morton, David Belada, Olivier Casasnovas, et al.. (2020). Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leukemia & lymphoma. 62(2). 368–376. 27 indexed citations

10.

Lindsay, Julian, Albert Kai-Sun Wong, Ian Kerridge, et al.. (2019). Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens. Bone Marrow Transplantation. 55(8). 1638–1641. 1 indexed citations

11.

Brown, David A., Anthony J. Dodds, Keith Fay, et al.. (2018). CD200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry. International Journal of Laboratory Hematology. 40(5). 533–539. 17 indexed citations

12.

Lindsay, Julian, Indy Sandaradura, Chris Arthur, et al.. (2017). Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. Journal of Antimicrobial Chemotherapy. 72(12). 3414–3419. 40 indexed citations

13.

Kumarasinghe, G., Andrew Parker, Ian Nivison‐Smith, et al.. (2015). Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. The Journal of Heart and Lung Transplantation. 34(11). 1406–1414. 38 indexed citations

14.

Bryant, Adam, Ian Nivison‐Smith, Anna Kalff, et al.. (2013). Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. Bone Marrow Transplantation. 49(1). 17–23. 10 indexed citations

15.

Arthur, Christopher, Brandon J. Aubrey, William Stevenson, et al.. (2012). Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients. Blood. 120(21). 3612–3612. 1 indexed citations

16.

Halter, Jörg, Michaël Schüpbach, Carlo Casali, et al.. (2010). Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplantation. 46(3). 330–337. 83 indexed citations

17.

Chen, Vivien, et al.. (2003). Extramedullary presentation of acute leukaemia: a case of myeloid/natural killer cell precursor leukaemia. Pathology. 35(4). 325–329. 9 indexed citations

18.

Atkinson, K, Keith Fay, Ian Nivison‐Smith, & K Downs. (1997). Lenograstim administration to HLA-identical donor–recipient pairs to accelerate marrow recovery post-transplant. Bone Marrow Transplantation. 19(1). 15–21. 6 indexed citations

19.

Atkinson, K, Anthony J. Dodds, Samuel T. Milliken, et al.. (1995). Autologous blood stem cell transplantation for haematological malignancy: treatment‐related mortality of 2%. Australian and New Zealand Journal of Medicine. 25(5). 483–489. 7 indexed citations

20.

Fay, Keith, Stephen O. Brennan, Howard Potter, et al.. (1993). Haemoglobin Manukau β67[E11] Val→Gly: transfusion‐dependent haemolytic anaemia ameliorated by coexisting alpha thalassaemia. British Journal of Haematology. 85(2). 352–355. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact